Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지

Clinical significance of serum vascular endothelial growth factor in Kawasaki disease

가와사끼병에서 혈청 Vascular Endothelial Growth Factor의 임상적 의의

  • Lee, Ho Seok (Department of Pediatrics, College of Medicine Chung-Ang University) ;
  • Yun, Sin Weon (Department of Pediatrics, College of Medicine Chung-Ang University) ;
  • Jung, Young Soo (Department of Pediatrics, College of Medicine Chung-Ang University) ;
  • Chae, Soo Ahn (Department of Pediatrics, College of Medicine Chung-Ang University) ;
  • Lim, In Seok (Department of Pediatrics, College of Medicine Chung-Ang University) ;
  • Lee, Dong Keun (Department of Pediatrics, College of Medicine Chung-Ang University) ;
  • Choi, Eung Sang (Department of Pediatrics, College of Medicine Chung-Ang University) ;
  • Yoo, Byung Hoon (Department of Pediatrics, College of Medicine Chung-Ang University) ;
  • Lee, Mi Kyung (Laboratory Medicine, College of Medicine Chung-Ang University)
  • 이호석 (중앙대학교 의과대학 소아과학교실) ;
  • 윤신원 (중앙대학교 의과대학 소아과학교실) ;
  • 정영수 (중앙대학교 의과대학 소아과학교실) ;
  • 채수안 (중앙대학교 의과대학 소아과학교실) ;
  • 임인석 (중앙대학교 의과대학 소아과학교실) ;
  • 이동근 (중앙대학교 의과대학 소아과학교실) ;
  • 최응상 (중앙대학교 의과대학 소아과학교실) ;
  • 유병훈 (중앙대학교 의과대학 소아과학교실) ;
  • 이미경 (중앙대학교 의과대학 진단검사의학교실)
  • Received : 2007.02.15
  • Accepted : 2007.08.16
  • Published : 2007.10.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Kawasaki disease is a systemic vasculitis, leading cause of pediatric acquired heart disease. Vascular endothelial growth factor (VEGF) has functions as vascular permeability factor, plays an important role in coronary artery lesion (CAL). We studied the clinical significance of serum VEGF in Kawasaki disease. Methods : Kawasaki group was 49 patients, and control group was 15 patients. Diagnosis followed AHA (American Heart Association) diagnostic criteria, with blood sampling in acute, subacute, and convalescent phase. Echocardiographic abnormalities were defined and the definition of intravenous gamma globulin (IVGG)-responsive and IVGG-resistant was determined. Results : Serum VEGF of Kawasaki group was significantly higher than of control group. Comparison of serum VEGF between CAL and non-CAL group, between carditis group and non-carditis group showed no significant differences. Subacute serum VEGF was statistically higher in IVGG-resistant group than in IVGG-responsive group, and serum VEGF of IVGG-resistant group in subacute phase was statistically higher than in the other phases. Serum VEGF of convalescent CAL and non-CAL group in acute and subacute phase had meaningful differences. Total fever duration and subacute serum VEGF had positive correlation. Acute serum VEGF had positive correlation with ESR and CRP, all phases serum VEGF had also positive correlation with WBC. Acute and subacute serum VEGF had negative correlations with hemoglobin and albumin. Conclusion : Serum VEGF can help to determine the severity of Kawasaki disease, especially subacute serum VEGF seems to be used as a prognostic factor of coronary complication. Afterward, further studies needed with more strict diagnostic criteria and more study groups.

목 적 : 가와사끼병은 전신성 혈관염으로 소아 후천성 심질환의 가장 흔한 원인이다. 혈관내피세포 생성인자는 미세혈관 투과성 및 혈관생성능력을 갖추고 있으며 가와사끼병에서 심장 합병증에 중요한 역할을 하는 것으로 알려져 있다. 가와사끼병에서 임상 양상, 심장 합병증, 감마글로불린 치료에의 반응 여부, 검사실 소견과 VEGF의 상관관계에 대하여 연구하였다. 방 법 : 가와사끼군은 49명을 대상으로 하였고, 대조군은 15명을 대상으로 하였다. 급성기, 아급성기, 회복기로 나누어 측정하였으며, 심장초음파 이상소견 및 감마글로불린 반응군 및 불응군을 정의하였다. 결 과 : 1) 가와사끼군과 대조군은 연령 및 체중에서 통계학적으로 유의한 차이는 없었다. 2) 급성 발열기 가와사끼군에서 혈청 VEGF가 대조군에 비해 유의하게 높았다. 3) 정형적 가와사끼군과 비정형 가와사끼군의 급성기 혈청 VEGF는 유의한 차이가 없었다. 4) 관상동맥 병변이 있는 군과 없는 군 간의 혈청 VEGF는 급성기와 아급성기 및 회복기에서 모두 유의한 차이가 없었다. 5) 심염이 있는 군과 없는 군 간의 혈청 VEGF는 급성기와 아급성기 모두에서 유의한 차이가 없었다. 6) 감마글로불린 반응군이 비반응군에 비해 급성기, 회복기 혈청 VEGF가 높았으나 유의한 차이는 없었고, 아급성기 혈청 VEGF는 불응군이 반응군에 비해 의미있게 높았다. 또한 감마글로불린 불응군 중에서 아급성기 혈청 VEGF가 급성기, 회복기에 비해 유의하게 높았다. 7) 회복기 관상동맥 변화 지속군과 비지속군의 급성기, 아급성기 혈청 VEGF의 차이는 의미 있었으나, 회복기 혈청 VEGF는 유의한 차이가 없었다. 8) 총 발열기간과 급성기 혈청 VEGF 간의 상관관계는 없었으나, 아급성기 혈청 VEGF는 뚜렷한 양의 상관관계를 보였다. 9) 급성기 혈청 VEGF는 적혈구침강속도, C-반응성단백과 양의 상관관계를 보였고 백혈구는 모든 시기의 혈청 VEGF와 뚜렷한 양의 상관관계를 보였다. 10) 급성기, 아급성기 혈청 VEGF는 혈색소와 뚜렷한 음의 상관관계를 보였으며 알부민과도 뚜렷한 음의 상관관계를 보였다. 결 론 : 혈청 VEGF는 가와사끼병의 중증도 판정에 도움을 줄 수 있으며 특히 아급성기 값이 심합병증의 예측인자로 사용 가능할 것으로 보인다. 검사실 소견과의 관계를 통해 염증반응지표와 밀접한 연관이 있는 것으로 생각되며 향후 더 엄격한 진단기준과 더 많은 대상 환아를 기초로 한 지속적인 연구가 필요할 것으로 사료된다.

Keywords

References

  1. Hirose S, Hamashima Y. Morphological observation on the vasculitis in the mucocutaneous lymph node syndrome: a skin biopsy study of 27 patients. Eur J Pediatr 1978;129: 17-27 https://doi.org/10.1007/BF00441370
  2. Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease : pathology and morphogenesis of the vascular changes. Jpn Circ J 1979:43:633-43 https://doi.org/10.1253/jcj.43.633
  3. Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y. Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999;83:337-9 https://doi.org/10.1016/S0002-9149(98)00864-9
  4. Yasukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, et al. Systemic production of vascular endothelial growth factor and frns-Iike tyrosine kinase-I receptor in acute Kawasaki disease. Circulation 2002;105:766-9 https://doi.org/10.1161/hc0602.103396
  5. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor gene is expressed differentially in normal tissues, macrophages, and tumors. Mol BioI Cell 1992;3:211-20 https://doi.org/10.1091/mbc.3.2.211
  6. Ferrara N, Henzel WJ. Pituitary follicular cells secret a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8 https://doi.org/10.1016/0006-291X(89)92678-8
  7. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrare N. Vascular endothelial growth factor is a screted angiogenic mitogen. Science 1989;246:1306-9 https://doi.org/10.1126/science.2479986
  8. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12 https://doi.org/10.1126/science.2479987
  9. Tischer E, Gosporadowicz D, Mitchell R, Silva M, Schilling J, Lau K, et al. Vascular endothelial growth factor : a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun 1989;165:1198-206 https://doi.org/10.1016/0006-291X(89)92729-0
  10. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: clinical observations of 50 cases (in Japanese). Arerugi 1967;16:178-222
  11. Ohno T, Igarashi H, Inoue K, Akazawa K, Joh-o K, Hara T. Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 2000;159:424-9 https://doi.org/10.1007/s004310051300
  12. Seko Y, Imai Y, Suzuki S. Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. Clin Sci 1997;92: 453-4 https://doi.org/10.1042/cs0920453
  13. Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajirna I, et al. Increased serum levels of vascular endothelial growth factor in Kawasaki disease. Pediatr Res 1998:44:5969
  14. Suzuki A, Miyagawa-Tomita S, Nakazawa M, Yutani C. Remodeling of coronary artery lesions due to Kawasaki disease. Japan Heart J 2000:41:245-56 https://doi.org/10.1536/jhj.41.245
  15. Suzuki A, Miyagawa-Tomita S, Komatsu K, Nishikawa T, Sakomura Y, Horie T, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease. Circulation 2000;101:2935-41 https://doi.org/10.1161/01.CIR.101.25.2935
  16. American Heart Association, Inc. Adapted in part from the Japan Kawasaki Disease Research Committee. Circulation 2001;103:335-6 https://doi.org/10.1161/01.CIR.103.2.335
  17. Rowley AH, Gonzalez-Crussi F, Gidding SS, Duffy CE, Shulman ST. Incomplete Kawasaki disease with coronary artery involvement. J Pediatr 1987;110:409-13 https://doi.org/10.1016/S0022-3476(87)80503-6
  18. Kurotobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatrics international 2002;44:1-4 https://doi.org/10.1046/j.1442-200X.2002.01508.x
  19. Rosenfeld EA, Corydon KE, Shulman ST. Kawasaki disease in infants less than one year of age. J Pediatr 1995;126: 524-9
  20. Burns JC, Wiggins JW, Toews WH, Newburger JW, Leung DY, Wilson H, et al. Clinical spectrum of Kawasaki disease in infants younger than 6 months of age. J Pediatr 1986; 109:759-63 https://doi.org/10.1016/S0022-3476(86)80689-8
  21. Takeshita S, Kawamura Y, Takabayashi H, Yoshida N, Nonoyama S. Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. Clinical and Experimental Immunology 2005;139:575-9 https://doi.org/10.1111/j.1365-2249.2005.02714.x
  22. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9 https://doi.org/10.1016/S0022-3476(05)80972-2
  23. Han RK, Silverman ED, Newman A, McCrindle BW. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Arch Pediatr Adolesc Med 2000;154:694-9 https://doi.org/10.1001/archpedi.154.7.694
  24. Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics 2000;105(6):E78 https://doi.org/10.1542/peds.105.6.e78
  25. Fukunishi M, Kikkawa M, Hamana K, Onodera T, Matsuzaki K, Matumoto Y, et al. Prediction of non-response to intravenous high-dose gammaglobulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6 https://doi.org/10.1067/mpd.2000.104815
  26. Durongpisitkul K, Soongswang J. Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C, et al. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8 https://doi.org/10.1007/s00246-002-0216-2
  27. Zee R, Murohara T, Lou Z, Zollmann F, Passeri J, Lekutat C, et al. Vascular endothelial growth factor/Vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997;95: 1030-7 https://doi.org/10.1161/01.CIR.95.4.1030
  28. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100:3131-9 https://doi.org/10.1172/JCI119868
  29. Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997; 3:879-86 https://doi.org/10.1038/nm0897-879
  30. Burns JC, Glode MP, Clarke SH, Wiggins J Jr, Hathaway WE. Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of artery aneurysms. J Pediatr 1984;105:206-11 https://doi.org/10.1016/S0022-3476(84)80114-6
  31. Yamakawa R, Ishii M, Sugimura T, Akagi T, Eto G, Iemura M, et al. Coronary endothelial dysfunction after Kawasaki disease: evaluation by intracoronary injection of acetylcholine. J Am Coll Cardiol 1998;31:1074-80 https://doi.org/10.1016/S0735-1097(98)00033-3
  32. Mitani Y, Okuda Y, Shimpo H, Uchida F, Hamanaka K, Aoki K, et al. Impaired endothelial function in epicardial coronary arteries after Kawasaki disease. Circulation 1997; 96:454-61
  33. Koren G, Lavi S, Rose V, Rowe R. Kawasaki disease : review of risk factors for coronary aneurysms. J Pediatr 1986;108:388-92 https://doi.org/10.1016/S0022-3476(86)80878-2
  34. Ichida F, Fatica NS, Engle MA, O'Loughlin JE, Klein AA, Snyder MS, et al. Coronary artery involvement in Kawasaki syndrome in Manhattan, New York : risk factors and role of aspirin. Pediatrics 1987;80:828-35
  35. Daniels SR, Specker B, Capannari TE, Schwartz DC, Burke MJ, Kaplan S. Correlates of coronary artery aneurysm formation in patients with Kawasaki disease. Am J Dis Child 1987;141:205-7
  36. Okada Y, Shinohara M, Kobayashi T, Inoue Y, Tomomasa T, Kobayashi T, et al. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. J Pediatr 2003;143:363-7 https://doi.org/10.1067/S0022-3476(03)00387-1
  37. Harada K, Yamaguchi H, Kato H, Nishibayashi Y, Ichiro S, Okazaki T, et al. Indication for intravenous gamma globulin treatment for Kawasaki disease. American Heart Association 1993:459-62
  38. Harada K. Intravenous gamma-globulin treatment in Kawasaki disease. Acta Paediatr Jpn 1991;33:805-10 https://doi.org/10.1111/j.1442-200X.1991.tb02612.x
  39. Beiser AS, Takahasha M, Baker AL, Sundel RP, Newburger JW. A predictive instrument for coronary artery aneurysms in Kawasaki disease. United States Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998;81:1116-20 https://doi.org/10.1016/S0002-9149(98)00116-7
  40. Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation 1993;87:1776-80 https://doi.org/10.1161/01.CIR.87.5.1776